Effect of Roflumilast on Chronic Obstructive Pulmonary Disease: a Systematic Review and Meta-analysis

Overview

Journal Ir J Med Sci

Specialty General Medicine

Date 2018 Feb 5

PMID 29397527

Citations 12

Authors

Lu-Fei Shen

Xiao-Dong Lv

Wen-Yu Chen

Qi Yang

Zhi-Xian Fang

Wei-Fen Lu

Affiliations

Soon will be listed here.

Abstract

Background: Randomized controlled trials (RCTs) of roflumilast effect on chronic obstructive pulmonary disease (COPD) have been reported in the last decade. The current meta-analysis was designed to systematically review and perform meta-analysis of the RCTs of roflumilast treatment in COPD.

Methods: Electronic databases including PubMed, EMBASE, Web of Science, and Cochrane clinical trials database were searched to identify RCTs of roflumilast treatment on COPD. The primary outcomes were effect of roflumilast on pre-bronchodilator FEV1, post-bronchodilator FEV1, and exacerbation rate. Secondary outcomes were effect of roflumilast on airway inflammation and adverse effect.

Results: A total of 11 RCTs were enrolled into the current analysis. Roflumilast significantly improved both pre-bronchodilator FEV1 (standardized difference in mean ± SD was 0.621 ± 0.161; 95% CI 0.306~0.936, p < 0.001) and post-bronchodilator FEV1 (standardized difference in mean ± SD was 0.563 ± 0.149, 95% CI 0.270~0.855, p < 0.001) compared with placebo. Roflumilast also significantly reduced exacerbation of COPD (standardized difference in mean ± SD 0.099 ± 0.020, 95% CI 0.061~0.138; p < 0.001) and suppressed airway inflammation (standardized difference in mean ± SD 1.354 ± 0.260, 95% CI 0.845~1.862, p < 0.001) compared with placebo. However, roflumilast significantly increased adverse effect such as diarrhea (rate ratio 2.945, 95% CI 2.453~3.536, p < 0.001) and weight loss (rate ratio 3.814, 95% CI 3.091~4.707, p < 0.001) compared with placebo.

Conclusion: These findings indicated that roflumilast treatment could improve COPD patients' lung function and reduce exacerbation, and that inhibition of airway inflammation by roflumilast might contribute to the beneficial effect of PDE-4 inhibitors on COPD.

Citing Articles

[Chronic obstructive pulmonary disease (COPD): eosinophilia and novel drug therapies].

Biener L, Pizarro C, Skowasch D Inn Med (Heidelb). 2024; 65(7):738-745.

PMID: 38831048 DOI: 10.1007/s00108-024-01725-z.

Management of Refractory Chronic Obstructive Pulmonary Disease: A Review.

Rahi M, Mudgal M, Asokar B, Yella P, Gunasekaran K Life (Basel). 2024; 14(5).

PMID: 38792564 PMC: 11122447. DOI: 10.3390/life14050542.

The Dosing Strategy to Improve Adherence to Roflumilast in Treatment for Chronic Obstructive Lung Disease: A Systemic Review and Meta-Analysis.

Lee J, Song J Int J Chron Obstruct Pulmon Dis. 2024; 19:655-663.

PMID: 38476122 PMC: 10928913. DOI: 10.2147/COPD.S440252.

Novel Vehicles For Drug Delivery in Atopic Dermatitis: A Narrative Review.

Farkouh C, Anthony M, Abdi P, Santiago N, Farkouh M Dermatol Pract Concept. 2023; 13(4).

PMID: 37992345 PMC: 10656133. DOI: 10.5826/dpc.1304a216.

Inhibition of Recruitment and Activation of Neutrophils by Pyridazinone-Scaffold-Based Compounds.

Moniot A, Braux J, Siboni R, Guillaume C, Audonnet S, Allart-Simon I Int J Mol Sci. 2022; 23(13).

PMID: 35806233 PMC: 9266889. DOI: 10.3390/ijms23137226.

References

Martinez F, Rabe K, Sethi S, Pizzichini E, McIvor A, Anzueto A . Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med. 2016; 194(5):559-67. DOI: 10.1164/rccm.201607-1349OC. View

Hanania N, Calverley P, Dransfield M, Karpel J, Brose M, Zhu H . Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2013; 108(2):366-75. DOI: 10.1016/j.rmed.2013.09.018. View

Calverley P, Rabe K, Goehring U, Kristiansen S, Fabbri L, Martinez F . Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374(9691):685-94. DOI: 10.1016/S0140-6736(09)61255-1. View

Spurzem J, Rennard S . Pathogenesis of COPD. Semin Respir Crit Care Med. 2005; 26(2):142-53. DOI: 10.1055/s-2005-869535. View

De Mey C, Nassr N, Lahu G . No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study. BMC Clin Pharmacol. 2011; 11:7. PMC: 3127977. DOI: 10.1186/1472-6904-11-7. View

ODonnell D, Bredenbroker D, Brose M, Webb K . Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2011; 39(5):1104-12. DOI: 10.1183/09031936.00096511. View

Chong J, Leung B, Poole P . Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013; (11):CD002309. DOI: 10.1002/14651858.CD002309.pub4. View

Grootendorst D, Gauw S, Verhoosel R, Sterk P, Hospers J, Bredenbroker D . Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007; 62(12):1081-7. PMC: 2094292. DOI: 10.1136/thx.2006.075937. View

Michalski J, Golden G, Ikari J, Rennard S . PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther. 2011; 91(1):134-42. DOI: 10.1038/clpt.2011.266. View

10.

Bateman E, Rabe K, Calverley P, Goehring U, Brose M, Bredenbroker D . Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011; 38(3):553-60. DOI: 10.1183/09031936.00178710. View

11.

Rennard S, Sun S, Tourkodimitris S, Rowe P, Goehring U, Bredenbroker D . Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. Int J Chron Obstruct Pulmon Dis. 2014; 9:657-73. PMC: 4075954. DOI: 10.2147/COPD.S55738. View

12.

Fabbri L, Calverley P, Izquierdo-Alonso J, Bundschuh D, Brose M, Martinez F . Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374(9691):695-703. DOI: 10.1016/S0140-6736(09)61252-6. View

13.

Perera W, Hurst J, Wilkinson T, Sapsford R, Mullerova H, Donaldson G . Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2006; 29(3):527-34. DOI: 10.1183/09031936.00092506. View

14.

Barnes N, Saetta M, Rabe K . Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast. BMC Pulm Med. 2014; 14:9. PMC: 3927659. DOI: 10.1186/1471-2466-14-9. View

15.

Rennard S, Calverley P, Goehring U, Bredenbroker D, Martinez F . Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res. 2011; 12:18. PMC: 3040135. DOI: 10.1186/1465-9921-12-18. View

16.

Bardin P, Kanniess F, Gauvreau G, Bredenbroker D, Rabe K . Roflumilast for asthma: Efficacy findings in mechanism of action studies. Pulm Pharmacol Ther. 2015; 35 Suppl:S4-10. DOI: 10.1016/j.pupt.2015.08.006. View

17.

Higgins J, Thompson S, Deeks J, Altman D . Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 2002; 7(1):51-61. DOI: 10.1258/1355819021927674. View

18.

Zheng J, Yang J, Zhou X, Zhao L, Hui F, Wang H . Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest. 2013; 145(1):44-52. DOI: 10.1378/chest.13-1252. View

19.

Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

20.

Hogg J, Chu F, Utokaparch S, Woods R, Elliott W, Buzatu L . The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(26):2645-53. DOI: 10.1056/NEJMoa032158. View